(Q43752173)

26 November 2017

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). (English)

1 reference

26 November 2017

Weiden PL

1

1 reference

PubMed ID

11578915

26 November 2017

Breitz HB

series ordinal

2

1 reference

26 November 2017

1 October 2001

1 reference

Critical Reviews in Oncology Hematology

26 November 2017

1 reference

26 November 2017

40

1 reference

26 November 2017

1

1 reference

26 November 2017

37-51

1 reference

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900133-0

7 January 2021

10.1016/S1040-8428(01)00133-0

Identifiers

DOI

1 reference

26 November 2017

1 reference

PubMed ID

11578915